Not cost-effective at zero price: valuing and paying for combination therapies in cancer,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Not cost-effective at zero price: valuing and paying for combination therapies in cancer
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2021-02-09 , DOI: 10.1080/14737167.2021.1879644
Nicholas R Latimer ₁ , Adrian Towse ₂ , Chris Henshall ₂

Affiliation

(2021). Not cost-effective at zero price: valuing and paying for combination therapies in cancer. Expert Review of Pharmacoeconomics & Outcomes Research: Vol. 21, Pharmacoeconomics in Oncology: Direct and Indirect Costs, pp. 331-333.

中文翻译：